Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Relamorelin - Allergan

Drug Profile

Relamorelin - Allergan

Alternative Names: BIM-28131; BIM-28163; RM 131

Latest Information Update: 04 Feb 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ipsen
  • Developer Allergan; Ipsen
  • Class Gastrokinetics; Growth hormone-releasing hormones; Peptides; Piperidines; Thiophenes
  • Mechanism of Action Ghrelin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Diabetic gastroparesis
  • Phase II Constipation; Gastrointestinal disorders
  • Discontinued Cachexia

Most Recent Events

  • 20 Dec 2018 Allegran initiates a phase-III extension study for Diabetic gastroparesis in USA (NCT03786380)
  • 20 Oct 2018 Updated adverse events data from a phase IIa trial in Diabetic gastroparesis presented at the 26th United European Gastroenterology Week (UEGW-2018)
  • 20 Oct 2018 Updated efficacy and adverse events data from a phase IIb trial in Diabetic gastroparesis presented at the 26th United European Gastroenterology Week (UEGW-2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top